Novel coronavirus outbreak: experience and challenges in imaging and beyond

ACE2 – a rational frontline therapy for COVID-19

Thursday, March 12, 2020
17:00 CET


Professor Penninger’s lecture “ACE2 – a rational frontline therapy for COVID-19” aims to shed light on the discovery and function of ACE2 (angiotensin converting enzyme 2). The lecture will also cover the relationship between ACE2 and renin–angiotensin system (RAS) – a hormone system responsible for systemic vascular resistance and for regulating blood pressure and fluid-electrolyte balance – in instances of lung injury. Furthermore, the lecture will highlight the predisposition of ACE2 as a SARS-CoV and SARS-CoV-2 receptor.

Prof. Josef Penninger

Austrian Professor Dr Josef Penninger is one of the world’s leading geneticists and molecular immunologists. Recipient of numerous prizes, he established the Viennese Institute of Molecular Biotechnology, and is the current Director of the Life Sciences Institute at the University of British Columbia in Canada. The main focus of his work has been autoimmune, bone, and heart and lung diseases, and cancers. APEIRON Biologics AG  a company Penninger founded, is currently tackling the ongoing outbreak of COVID-19 in China and is scheduled to start a pilot clinical trial for their newly developed drug that is supposed to decrease mortality in those affected by the virus.
(image: ©IMBA)

Free access 

ESR supports the global fight against COVID-19 and makes this session free to access.

The live stream via ESR Connect is free of charge.